Rubitecan

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Rubitecan
Rubitecan.svg
Systematic (IUPAC) name
(4S)-4-ethyl-4-hydroxy-11-nitro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
Clinical data
Legal status ?
Routes Oral
Identifiers
CAS number 91421-42-0 YesY
ATC code None
PubChem CID 11954380
UNII H19C446XXB N
ChEMBL CHEMBL77305 N
Synonyms (19S)-19-ethyl-19-hydroxy-10-nitro-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione
Chemical data
Formula C20H15N3O6 
Mol. mass 393.349 g/mol
 N (what is this?)  (verify)

Rubitecan (INN, marketing name Orathecin) is an oral topoisomerase inhibitor, developed by Supergen.

History[edit]

On January 27, 2004, Supergen announced that it has completed the submission of an NDA for rubitecan to the US FDA, [1] and was accepted for filing on March 2004.[2]

On January 2005, Supergen withdrew the NDA for rubitecan, based on feedback indicating that the current data package would not be sufficient to gain US approval,[3] and on January 2006, the Marketing Authorization Application (MAA) filed with the European Medicines Agency (EMA) was also withdrawn.[4]

References[edit]